WuXi Biologics is a global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics. Our global footprint includes sites throughout the United States, Europe, China and Singapore. The WuXi Biologics King of Prussia (KOP) site is focusing on biologics, vaccine, and other biotherapeutic R&D. Services start with early-stage process and analytical development through late-stage process development and characterization and corresponding CMC strategy and management. This location is home to a growing team of near 100 staff members.
Established in October 2020, the KOP facility, located within the campus of The Discovery Labs, provides expert services for biologics and vaccine developers and is yet another key component to our single-source, concept to commercialization drug development platform we provide to our global clients and partners.
- 33,000 sq. ft. of biologics of Biosafety Level 2 R&D laboratories
Capabilities and Capacities:
- Rapid protein production to support drug discovery R&D
- Biologics and vaccines feasibility / developability
- Early- and late-stage process development
- Analytical development and QC testing
- CMC strategy and management
- Near 100 highly skilled staff
Attractive Region for Job Opportunities:
The greater Philadelphia region’s Cellicon Valley has a rich history of life science innovations that revolutionized healthcare and is emerging as a leader in the research and development of novel therapeutic modalities – a hub for the next generation of medicine. As we grow, so does the community of qualified scientists.
If you wish to contact us about a job or a career at WuXi Biologics, please go to the Careers section of our website.